Our Products in Europe
All of our products are prescription-only medicines (POM). If more information is required, please refer to the local SPC or PIL.

ABILIFY® (aripiprazole)

ABILIFY contains the active substance aripiprazole. It is available in different forms (tablets, oral solution and a solution for injection). ABILIFY is used in the treatment of schizophrenia and moderate to severe manic episodes in Bipolar I Disorder. Click here for ABILIFY orodispersible SmPC Click here for ABILIFY orodispersible PIL Click here for ABILIFY tablets SmPC Click here for ABILIFY tablets PIL Click here for ABILIFY oral solution SmPC Click here for ABILIFY oral solution PIL

Abilify Maintena® (aripiprazole)

Abilify Maintena contains the active substance aripiprazole. It is available as a powder and solvent to be made into a suspension for injection. It is used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with oral aripiprazole. Click here for Abilify Maintena SmPC Click here for Abilify Maintena PIL

Samsca® (tolvaptan)

Samsca contains the active substance tolvaptan. It is available as a tablet. Samsca is used to treat adults with hyponatraemia (abnormally low levels of sodium in the blood) caused by a condition called ‘syndrome of inappropriate antidiuretic-hormone secretion’ (SIADH). Click here for Samsca SmPC  Click here for Samsca PIL

JINARC® (tolvaptan)

JINARC contains the active ingredient tolvaptan and it is available as a tablet. It is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease. Click here for JINARC SmPC Click here for JINARC PIL

SPRYCEL® (dasatinib)

SPRYCEL is indicated for the treatment of adult patients with:
  • newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
  • chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.
  • Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
The Marketing Authorisation Holder of the drug is Bristol-Myers Squibb Pharma EEIG. Click here for SPRYCEL SmPC  Click here for SPRYCEL PIL

Pletal® (cilostazol) 

Pletal contains the active substance cilostazol. It is available as a tablet. Pletal is indicated for the improvement of maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II). Please refer to local country sites as Pletal is not available in some countries. Click here for Pletal SmPC Click here for Pletal PIL

 

For more information about Otsuka’s global portfolio, please visit our global website. For information on products that are currently in the pipeline, please visit the Otsuka Holdings Co., Ltd. website.

Date of preparation: August 2018

Reference OPUK/1017/GEN/1165(a-g)

)